Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

675P - Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)

Date

14 Sep 2024

Session

Poster session 01

Topics

Targeted Therapy

Tumour Site

Presenters

Lin Shen

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

L. Shen1, D. Liu2, J.J.W. Park3, Z. Zhao4, B. Gao5, B. Liu6, J. Wu7, J. Zhang8, H. Zong9, J. Ruan10, X. Zhang11, J. dai12

Author affiliations

  • 1 Gi Oncology Department, Peking University Cancer Hospital and Institute, 100142 - Beijing/CN
  • 2 Medical Oncology, Peking University Cancer Hospital and Institute, 100142 - Beijing/CN
  • 3 Biomedical Sciences Department-level 1, Macquarie University - Faculty of Medicine, Health and Human Sciences, 2109 - Sydney/AU
  • 4 Clinical Medicine, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., 215024 - Suzhou/CN
  • 5 Haematology And Cancer Care Center, Blacktown Hospital, 2148 - Blacktown/AU
  • 6 Department Of Internal Medicine Oncology,, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 250117 - Jinan/CN
  • 7 Clinical Research, Fudan University Cancer Institute, 200032 - Shanghai/CN
  • 8 Department Of Medical Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 9 Oncology Dept., The First Affiliated Hospital of Zhengzhou University, 450052 - Zhengzhou/CN
  • 10 Medical Oncoogy, First Affiliated Hospital of Zhejiang University School of Medicine, 310000 - Hangzhou/CN
  • 11 Medical Oncoogy, The First Affiliated Hospital, Zhejiang University, 310003 - Hangzhou/CN
  • 12 Radiation Oncology, Zhongnan Hospital of Wuhan University, Wuhan/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 675P

Background

JSKN003 is a novel HER2-directed antibody-drug conjugate (ADC) conjugated to a topoisomerase I inhibitor via a dibenzocyclooctyne tetrapeptide linker on the glycans of a humanized bispecific antibody. JSKN003-101 and JSKN003-102 is dose escalation and expansion studies in Australian and Chinese patients (pts) with metastatic solid tumors.

Methods

This is pooled analysis from pts enrolled in JSKN003-101 and JSKN003-102 with histologically documented HER2-positive (IHC 3+) solid tumors who failed prior systemic therapies, received JSKN003 monotherapy intravenously Q3W. The objectives were safety and efficacy of JSKN-003.

Results

As of 15th Mar 2024, 24 pts (7 CRC, 5 GC, 3 ESCA, 2 OC, 2 BTC, and 5 others) were enrolled and JSKN003 dosed across 6 dose levels, including 2.1 mg/kg, 4.2 mg/kg, 5.2 mg/kg, 6.3 mg/kg, 7.3 mg/kg and 8.4 mg/kg. 10 pts (41.7%) received ≥ 3 prior lines of therapy,6 pts(25%) received anti-HER2 ADC. The median duration of treatment was 13.9 (range,9.4,19.8) weeks, and 20 pts (83.3%) remained on treatment. Treatment-related adverse events (TRAEs) occurred in 23 pts (95.8%), and the mostly common grade 1 and 2 TRAEs were diarrhea (62.5%) and nausea (58.3%), infusion related reaction (29.2%), fatigue (25.0%).5 pts (20.8%) experienced grade ≥3 TRAEs, were neutropenia (8.3%), vomiting (4.2%), fatigue (4.2%) and abdominal discomfort (4.2%). 2 pts had interstitial lung disease, grade 2 (occurred in 6.3 mg/kg), both recovered thereafter. No TRAE led to death or discontinuation. 22 pts with tumor assessment, the ORR and DCR were 72.7% (95%CI: 49.8, 89.3) and 95.5% (95%CI: 77.2, 99.9). 5 pts who received prior anti-HER2 ADC, the ORR was 80% and median DOR was more than 30 weeks.

Conclusions

JSKN003 was well tolerated with encouraging preliminary antitumor activity in heavily pretreated pts with advanced HER2-positive (IHC ≥ 3+) solid tumors, which support further clinical development.

Clinical trial identification

NCT05494918; NCT05744427.

Editorial acknowledgement

Legal entity responsible for the study

Alphamab Oncology.

Funding

Alphamab Oncology.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.